Sun Pharma

Sun Pharma to Acquire Checkpoint Therapeutics

Indian generic drug maker Sun Pharma agreed to acquire US immunotherapy and targeted oncology company Checkpoint Therapeutics for an upfront value of $355 million. The transaction is expected to be completed in the second quarter of 2025 and is subject to customary closing conditions.

News

India's Sun Pharma, US Merck in Generics Joint Venture

Top-Feature

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.